Corcept Therapeutics (CORT) EBIAT (2016 - 2025)
Corcept Therapeutics (CORT) has disclosed EBIAT for 15 consecutive years, with $24.3 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 21.0% to $24.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $99.7 million through Dec 2025, down 29.43% year-over-year, with the annual reading at $99.7 million for FY2025, 29.43% down from the prior year.
- EBIAT hit $24.3 million in Q4 2025 for Corcept Therapeutics, up from $19.7 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $47.2 million in Q3 2024 to a low of $15.9 million in Q1 2023.
- Historically, EBIAT has averaged $28.0 million across 5 years, with a median of $27.6 million in 2023.
- Biggest five-year swings in EBIAT: surged 88.87% in 2023 and later plummeted 58.34% in 2025.
- Year by year, EBIAT stood at $32.1 million in 2021, then tumbled by 48.21% to $16.6 million in 2022, then soared by 88.87% to $31.4 million in 2023, then dropped by 1.94% to $30.7 million in 2024, then decreased by 21.0% to $24.3 million in 2025.
- Business Quant data shows EBIAT for CORT at $24.3 million in Q4 2025, $19.7 million in Q3 2025, and $35.1 million in Q2 2025.